Fibroblast Growth Factor 19 (FGF19): From Metabolic Regulation to Cancer Therapeutic Target and ANT BIO PTE. LTD.'s Antibody Solutions

1. Concept: Fibroblast Growth Factor 19 (FGF19)

Fibroblast Growth Factor 19 (FGF19) is a key member of the endocrine fibroblast growth factor (eFGF) family. Primarily synthesized and secreted by epidermal cells of the skin, subcutaneous tissues, and smooth muscle cells of visceral organs, FGF19 is encoded by the FGF19 gene located on chromosome 11q13—one of the most frequently amplified chromosomal regions in human cancers, with amplification levels serving as a predictor of anti-FGF19 drug efficacy.

Distinguished by low heparin-binding affinity, FGF19 subfamily proteins enter systemic circulation to exert endocrine functions. They play a pivotal role in regulating bile acid, glucose, lipid, and energy metabolism, maintaining metabolic homeostasis. Beyond metabolic regulation, FGF19 is closely linked to cancer development and progression, with elevated expression observed in hepatocellular carcinoma (HCC), lung cancer, colon cancer, breast cancer, thyroid cancer, prostate cancer, and cholangiocarcinoma. Its dual role in metabolism and oncogenesis makes it a versatile target for both metabolic disorder management and cancer therapy.

2. Research Frontiers of FGF19 in Metabolism and Cancer

Contemporary research on FGF19 focuses on expanding its therapeutic applications and optimizing targeted strategies. A key frontier is the development of highly selective FGFR4 inhibitors and FGF19 antibodies to treat FGF19-amplified cancers, particularly HCC, while minimizing off-target effects. Another prominent direction involves exploring FGF19 analogs (e.g., Aldafermin) for metabolic disorders like non-alcoholic steatohepatitis (NASH) and cholestatic diseases, leveraging their ability to regulate bile acid synthesis and hepatic fat deposition. Additionally, research is validating FGF19 as a companion diagnostic biomarker for patient stratification, ensuring targeted therapies are administered to individuals with FGF19 amplification or overexpression. Furthermore, combining FGF19-targeted therapies with immune checkpoint inhibitors or chemotherapy is being investigated to enhance antitumor efficacy in advanced cancers.

3. Research Significance of FGF19

FGF19 research holds profound implications for addressing global health challenges:

• Cancer therapy breakthroughs: HCC, the fourth leading cause of cancer-related deaths with a five-year survival rate <20%, benefits from FGF19-targeted therapies—approximately 30% of HCC patients overexpress FGF19/FGFR4, offering a large patient population for treatment.
• Metabolic disorder management: FGF19’s role in bile acid and energy metabolism provides new avenues for treating NASH, primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).
• Early diagnosis and prognosis: FGF19 gene amplification and protein overexpression correlate with tumor progression, size, and poor prognosis, serving as a valuable biomarker for early HCC detection and risk stratification.
• Translational potential: Preclinical and clinical success of FGFR4 inhibitors (e.g., BLU554, BPI-43487) and FGF19 analogs validates the target’s utility, driving the development of novel therapeutic modalities.
• Precision medicine advancement: FGF19-based companion diagnostics enable personalized treatment strategies, improving therapeutic outcomes and reducing unnecessary interventions.

4. Relevant Mechanisms, Research Methods and Product Applications

4.1 Core Mechanisms of FGF19 in Metabolism and Cancer

FGF19-FGFR4-KLB Signaling Pathway

FGF19 acts as an intestinal hormone induced by bile acid nuclear receptors post-prandially. It selectively binds to fibroblast growth factor receptor 4 (FGFR4) with the assistance of the co-receptor β-Klotho (KLB), forming a ternary complex that induces FGFR4 dimerization and autophosphorylation. This activation triggers downstream signaling pathways, including Ras-Raf-ERK1/2 MAPK and PI3K-Akt, which regulate cell proliferation, inhibit apoptosis, and suppress NF-κB signaling. The C-terminal region of FGF19 mediates its specific interaction with KLB, distinguishing it from other eFGF family members.

Role in HCC Oncogenesis

In HCC, FGF19 gene amplification drives abnormal activation of the FGF19-FGFR4 pathway. FGF19 regulates bile acid synthesis via negative feedback, and its overexpression—with KLB assistance—promotes liver cancer cell proliferation, induces epithelial-mesenchymal transition (EMT), and inhibits apoptosis. This dysregulation contributes to HCC development and progression, making the FGF19-FGFR4 pathway a prime therapeutic target.

4.2 Key Research Methods for FGF19 Study

• Molecular biology techniques: RT-PCR and next-generation sequencing (NGS) for detecting FGF19 gene amplification and mRNA expression.
• Protein detection methods: Western blot, immunohistochemistry (IHC), and ELISA for quantifying FGF19 protein levels in tissues and serum.
• Functional assays: Cell proliferation, apoptosis, and migration assays to evaluate the impact of FGF19 pathway activation or inhibition.
• Animal models: HCC xenograft models and genetically engineered mice to validate FGF19-targeted therapies in vivo.
• Clinical trials: Phase I/II trials to assess the safety and efficacy of FGFR4 inhibitors, FGF19 antibodies, and analogs in cancer and metabolic disorder patients.

4.3 Product Applications of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. delivers high-performance antibody solutions for FGF19 research and clinical translation through its Starter sub-brand—specializing in recombinant antibodies. All products are developed using advanced recombinant rabbit monoclonal antibody platforms, validated for specificity, sensitivity, and stability, and comply with EU 98/79/EC, ISO9001, and ISO13485 certifications. Key offerings include:

• FGF-19 Recombinant Rabbit mAb (S0B2328, SDT-1070-17): Validated in human hepatocellular carcinoma, liver, and gallbladder tissues, this antibody exhibits exceptional specificity and sensitivity for FGF19. It enables accurate detection of FGF19 protein expression via IHC, Western blot, and ELISA, supporting companion diagnostic development, patient stratification, and preclinical research.
• Application value: This antibody serves as a high-quality tool for identifying FGF19-overexpressing tumors, evaluating treatment response, and validating FGF19-targeted therapies, empowering researchers and clinicians in oncology and metabolic disease fields.

5. Brand Mission of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. is dedicated to empowering global life science research and clinical practice through high-quality, innovative reagents and professional services. As a leading provider of life science solutions, the company offers a comprehensive portfolio including antibodies, recombinant proteins, ELISA kits, and general laboratory reagents, with three specialized sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Leveraging advanced R&D platforms—including recombinant antibody development (rabbit/mouse monoclonal), protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—ANT BIO PTE. LTD. adheres to the principles of "precision, reliability, and customer-centricity." The company strives to deliver cost-effective products and tailored support to researchers, clinicians, and biopharmaceutical partners, accelerating the translation of scientific discoveries into improved patient care and advancing the global fight against cancer and metabolic disorders.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.